Drug and device costs could spike if the U.S. ultimately hits Chinese goods with additional levies as part of an escalating trade spat.

Several medical product industry groups told Bloomberg Law it’s too early to tell what the exact impact will be of a directive President Donald Trump issued in response to what he called unfair trade practices.

continue reading at: www.bna.com